ASURAGEN, INC.

Asuragen is a molecular diagnostics company specializing in genetic carrier screening and precision oncology testing. Founded in 2006 and acquired by Bio-Techne Corporation in 2021, the company develops advanced diagnostic solutions utilizing proprietary chemistries and miRNA-based technologies. Their product portfolio includes genetic testing kits for inherited disorders (Fragile X, CFTR, SMN1/2, HTT), precision oncology solutions for chronic myeloid leukemia (CML) and solid tumor monitoring, custom molecular quality controls, and armored RNA controls. The AmplideX product line encompasses PCR/CE-based assays optimized for clinical laboratories. Asuragen operates a GMP-compliant manufacturing facility and CLIA-certified laboratory, serving clinical diagnostics and research applications across oncology, genetic disorders, and carrier screening markets. The company maintains strategic partnerships and distributes products across North America and EMEA regions.